Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Bittermelon Reduces Heart Risk in Diabetics

PESHAWAR, Pakistan – A study out of Pakistan shows bitter melon reduces the risk of cardiovascular problems in diabetics more effectively than glibenclamide.

The study was published in the January 2014 edition of Nutrition Journal.

Bitter melon has been used in Asia to treat diabetes for generations, but clinical trials show conflicting conclusions regarding its effectiveness.

The current study assessed the hypoglycemic and antiatherogenic effects as well as the safety of two different doses of bitter melon with glibenclamide.

Three randomized groups with a total of 95 participants were used. Group I and group II received bitter melon (2 g/day and 4 g/day respectively) and group III received glibenclamide (5 mg/day) for 10 weeks. Glycemic control and antiatherogenic effects were determined by assessing glycohemoglobin (HbA1-c), fasting plasma glucose, 2 hour oral glucose tolerance test, plasma sialic acid, systolic blood pressure, blood lipids and atherogenic index at different time periods.
This study concludes that bitter melon has a weaker hypoglycemic effect, but improves the diabetes-associated cardiovascular risk factors more effectively than glibenclamide.

“I would be interested in seeing a study that compared these therapeutic interventions for a longer period of time,” said Dr. Anne Williams, ND, LAC. “Bitter melon is a food that is recommended for frequent consumption by many different cultures. It is possible that 10 weeks is not long enough to see its full effect on blood sugar regulation. Study length aside, it is encouraging to see the use of traditional foods being studied for diabetes and heart disease. We need to encourage patients to change their diets and to see food as medicine.”

http://www.nutritionj.com/content/14/1/13
cipro no prescription
Buy Cialis no prescription